1. Home
  2. WAL vs MDGL Comparison

WAL vs MDGL Comparison

Compare WAL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WAL
  • MDGL
  • Stock Information
  • Founded
  • WAL 1994
  • MDGL 2011
  • Country
  • WAL United States
  • MDGL United States
  • Employees
  • WAL N/A
  • MDGL N/A
  • Industry
  • WAL Major Banks
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • WAL Finance
  • MDGL Health Care
  • Exchange
  • WAL Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • WAL 7.8B
  • MDGL 6.8B
  • IPO Year
  • WAL 2005
  • MDGL N/A
  • Fundamental
  • Price
  • WAL $74.45
  • MDGL $294.64
  • Analyst Decision
  • WAL Strong Buy
  • MDGL Strong Buy
  • Analyst Count
  • WAL 15
  • MDGL 10
  • Target Price
  • WAL $95.33
  • MDGL $420.63
  • AVG Volume (30 Days)
  • WAL 1.0M
  • MDGL 373.7K
  • Earning Date
  • WAL 04-21-2025
  • MDGL 05-01-2025
  • Dividend Yield
  • WAL 2.04%
  • MDGL N/A
  • EPS Growth
  • WAL 6.13
  • MDGL N/A
  • EPS
  • WAL 7.28
  • MDGL N/A
  • Revenue
  • WAL $3,049,400,000.00
  • MDGL $317,383,000.00
  • Revenue This Year
  • WAL $13.35
  • MDGL $230.69
  • Revenue Next Year
  • WAL $9.86
  • MDGL $74.76
  • P/E Ratio
  • WAL $10.23
  • MDGL N/A
  • Revenue Growth
  • WAL 11.37
  • MDGL N/A
  • 52 Week Low
  • WAL $56.70
  • MDGL $200.08
  • 52 Week High
  • WAL $98.10
  • MDGL $377.46
  • Technical
  • Relative Strength Index (RSI)
  • WAL 57.81
  • MDGL 39.29
  • Support Level
  • WAL $70.45
  • MDGL $287.46
  • Resistance Level
  • WAL $75.71
  • MDGL $349.00
  • Average True Range (ATR)
  • WAL 2.49
  • MDGL 17.20
  • MACD
  • WAL 1.03
  • MDGL -2.36
  • Stochastic Oscillator
  • WAL 90.51
  • MDGL 11.67

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: